Cleerly Health - FloodGate Medical

Trusted by Leading Experts in Cardiac Imaging

About Us

Cleerly is a health technology company dedicated to transforming the diagnosis and prevention of heart disease through advanced imaging and AI-powered analysis. Heart disease remains the leading cause of death worldwide, often going undetected until serious events like heart attacks occur. Cleerly developed a proprietary, FDA-cleared software platform that uses coronary computed tomography angiography (CCTA) to precisely identify, quantify, and characterize atherosclerotic plaque in the coronary arteries. This enables earlier, more personalized management of heart disease risk. The company continues to expand its suite of AI-driven cardiovascular solutions, working with healthcare providers, imaging centers, and health systems to improve patient outcomes through proactive, data-driven heart care.

Look at the Leaders of Cleerly

James K. Min, MD

Founder & CEO

James Earls, MD

Chief Medical Officer

Jim Hartman

Chief Commercial Officer

Featured Innovations

Cleerly | ISCHEMIA

Cleerly ISCHEMIA is a first-of-its-kind, FDA-cleared heart disease evaluation that uses 37 measures of heart health to determine likelihood of coronary artery ischemia at a per-vessel level. Cleerly ISCHEMIA uses machine learning and concise reporting to aid physicians in personalizing patient treatment, including the planning of interventional treatments such as stent placement.

Cleerly | Plaque Analysis

Not All Plaque and Plaque Analysis Software Are the Same, Cleerly’s AI-enabled CCTA solution provides comprehensive, accurate, and trackable insights to personalize heart attack prevention.

Vessel-by-Vessel Detail
Precision phenotyping for each artery and branch with stenosis quantification and vascular remodeling scores

Comprehensive Plaque Assessment
At-a-glance view of characterized plaque volume by coronary region

Stenosis Scoring
Clear and concise summary of identified stenoses by severity

Supports Next-Gen Hardware
Advanced segmentation on photon-counting CT

News and Stories

AI Meets Value-Based Care: Cleerly and Cardiac Care Alliance Join Forces to Revolutionize Heart Disease Detection

May 6, 2025 (DENVER) – Cleerly, the leader in cardiovascular imaging, and Cardiac Care Alliance, leader in value-based cardiovascular care solutions, today announced a strategic partnership to enhance cardiovascular care delivery across the healthcare ecosystem. This collaboration will integrate Cleerly’s advanced AI-powered coronary artery assessment technology with Cardiac Care Alliance’s cardiovascular care network.

Cleerly Unveils Groundbreaking Late-Breaking Clinical Trial Results Demonstrating AI-QCT's Predictive Power for Women’s Cardiovascular Risk at ACC.25

March 31, 2025 (DENVER) — Cleerly, the leader in cardiovascular AI imaging, has announced revolutionary findings from its late-breaking clinical trial presented at the American College of Cardiology’s Annual Scientific Session + Expo (ACC.25) in Chicago, Illinois. The study, titled “Artificial Intelligence-based Quantitative Computed Tomography (AI-QCT) Coronary Plaque Features Predict Risk More Pronounced in Females: The International Multicentric Registry CONFIRM2,” was led by Gudrun M. Feuchtner, MD, MBA, and presented during the Clinical and Investigative Horizons I session on March 31st, 2025. This research has also been accepted for simultaneous publication in Circulation: Cardiovascular Imaging, a peer-reviewed journal of the American Heart Association.

Cleerly to Present Late-Breaking Clinical Trial Results on Cardiovascular Risk in Women at ACC.25

March 27, 2025 (CHICAGO) — Cleerly, the leader in cardiovascular AI imaging, announces its participation in the American College of Cardiology Annual Scientific Session + Expo (ACC.25) from March 29-31, 2025, at the McCormick Place Convention Center in Chicago, Illinois. Cleerly will share its late-breaking findings on Artificial Intelligence-based Quantitative Computed Tomography’s (AI-QCT’s) role in identifying risks of future major adverse cardiovascular events (MACE) in women. Onsite, Cleerly will demonstrate the company’s AI-enabled coronary computed tomography angiography (CCTA) solution to help guide personalized prognosis, diagnosis, and treatment of coronary artery disease (CAD).

Looking to stand out from the crowd during your job search? Click below to gain access to our top tips & tools for candidates during the hiring process!

Recruiting Done Differently.

Improving lives by uniting great people with great companies.

Sign up for our Monthly Newsletter

We’re committed to sharing up-to-date industry insights, our newest career opportunities, and valuable tools to support you throughout your next job search. Let’s stay connected!